Engineered soluble ACE2 receptor: Responding to change with change

SARS coronavirus 2 (SARS-CoV-2) invades the human body by binding to major receptors such as ACE2 via its S-spike protein, so the interaction of receptor-binding sites has been a hot topic in the development of coronavirus drugs. At present, the clinical progress in monoclonal antibody therapy that occurred early in the pandemic is gradually showing signs of slowing. While recombinant soluble ACE2, as an alternative therapy, has been modified by many engineering methods, both the safety and functional aspects are approaching maturity, and this therapy shows great potential for broadly neutralizing coronaviruses, but its progress in clinical development remains stalled. Therefore, there are still several key problems to be considered and solved for recombinant soluble ACE2 to be approved as a clinical treatment as soon as possible.

Abstract licence: CC BY

1. 10.

   Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig · 2020

2. 13.

   Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies · 2020

3. 14.

   Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 · 2020

4. 17.

   Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 · 2020

5. 18.

   Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine · 2020

6. 22.

   An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants · 2021

7. 23.

   Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2 · 2021

8. 29.

   Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies · 2021

23 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.